Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP +1.42%76 Net Margin % is 21.69% as of Dec. 2025. GuruFocus rates LTS:0DRP with a GF Score™ of 76/100 and a GF Value™ of €2.71 (Fairly Valued). The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Biohit Oyj ranks better than 86.03% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Biohit Oyj's Net Income for the
six
months ended in Dec. 2025 was €1.80 Mil. Biohit Oyj's Revenue for the
six
months ended in Dec. 2025 was €8.30 Mil. Therefore, Biohit Oyj's net margin for the quarter that ended in Dec. 2025 was 21.69%.
The historical rank and industry rank for Biohit Oyj's Net Margin % or its related term are showing as below:
LTS:0DRP'
s Net Margin % Range Over the Past 10 Years
Min: -46.51 Med: -4.31 Max: 68.37
Current: 17.2
LTS:0DRP's Net Margin % is ranked better than 86.03% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs LTS:0DRP: 17.20
Biohit Oyj (LTS:0DRP) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biohit Oyj Net Margin % Related Terms
Biohit Oyj Net Margin % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Biohit Oyj's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a Net Margin % of 21.69% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #114 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is Biohit Oyj's Net Margin % too high?
Biohit Oyj's current Net Margin % is 21.69%. The Medical Devices & Instruments industry median Net Margin % is 2.07. Biohit Oyj's value of 21.69% is 947.8% above this industry median. Based on the distribution chart, Biohit Oyj ranks #114 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #114 out of 816 companies for Net Margin %. This places Biohit Oyj in the top 14% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. Biohit Oyj's value of 21.69% is 947.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current Net Margin % of 21.69% is 947.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Net Margin % is 21.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.71, compared to a current price of €2.85 — trading 5.2% above its estimated fair value. The current Net Margin % is 21.69% and 947.8% above the Medical Devices & Instruments industry median of 2.07. Biohit Oyj's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Net Margin % is 21.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.85 is trading 5.2% above its estimated GF Value™ of €2.71.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
Net Margin %: 21.69%
GF Value™: €2.71 vs. price of €2.85 (5.2% above fair value)
Industry Position: 947.8% above the Medical Devices & Instruments median (#114 of 816)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
76GF Score
Get the complete analysis for LTS:0DRP
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
